Absci (ABSI)

• Market cap: $391M
• 1 day: 1.32%
• 5 days: -4.06%
• 1 month: 22.31%
• 3 months: -19.63%
• 6 months: -25.85%
• Year to date: 13.28%
• 1 year: -35.23%
• 5 years: -85.78%
• 10 years: -85.78%
• Sector: Healthcare
• Industry: Biotechnology

About: Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Employees: 157

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

121% more call options, than puts

Call options by funds: $850K | Put options by funds: $384K

55% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 22

34% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 32

7% more funds holding

Funds holding: 122 [Q3] → 131 (+9) [Q4]

0.56% more ownership

Funds ownership: 63.74% [Q3] → 64.31% (+0.56%) [Q4]

30% less capital invested

Capital invested by funds: $277M [Q3] → $194M (-$83M) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $7 128% upside
• Avg. target: $8.75 185% upside
• High target: $10 226% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Keybanc Scott Schoenhaus 54% 1-year accuracy 21 / 39 met price target	193% upside $9	Overweight Maintained	16 Apr 2025
Needham Gil Blum 18% 1-year accuracy 29 / 158 met price target	193% upside $9	Buy Reiterated	9 Apr 2025
Guggenheim Vamil Divan 40% 1-year accuracy 12 / 30 met price target	226% upside $10	Buy Reiterated	20 Mar 2025
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 57 / 192 met price target	128% upside $7	Buy Reiterated	19 Mar 2025